July 31, 2022

Anavex Announces Breakthrough in Alzheimer’s Disease Research Introduction: A recent study has revealed promising results in the treatment of Alzheimer’s and Parkinson’s disease through the use of ANAVEX®2-73. The expression levels of pathological dysregulated neurodegenerative genes associated with both diseases showed significant restoration after receiving this therapeutic treatment. Study Findings: The study showed that ANAVEX®2-73…

The Impact of Securities Lawsuits on Investors and the Financial Market Introduction Recently, the Rosen Law Firm issued a reminder to investors who purchased securities of TG Therapeutics, Inc. between January 15, 2020, and May 31, 2022, regarding an upcoming lead plaintiff deadline. This development has raised concerns among investors and highlighted the importance of…